Humacyte, Inc. [Rocket]

Overview

Humacyte, Inc.

Add to portfolio

Recent News + Filings (All items)

Date Filed	Type	Description
10/10/2023	4	Form 4 - Statement of changes in beneficial ownership of securities:
10/10/2023	4	Form 4 - Statement of changes in beneficial ownership of securities:
08/21/2023	4	Niklason Laura E (President, CEO and Director) has filed a Form 4 on Humacyte, Inc.
08/21/2023	4	Dougan Brady W (Director) has filed a Form 4 on Humacyte, Inc.
08/21/2023	4	Ayabudge LLC (10% Owner) has filed a Form 4 on Humacyte, Inc.
08/17/2023	144	Form 144 - Report of proposed sale of securities:
08/14/2023	10-Q	Quarterly Report for the period ended June 30, 2023

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20
Revenues	1.6	1.3	1.5
Revenue growth	23.9%	-15.3%
Cost of goods sold	0.0	0.0	0.0
Gross profit	1.6	1.3	1.5
Gross margin	100.0%	100.0%	100.0%
Research and development	63.3	61.3	54.1
General and administrative	22.9	21.1	12.0
EBITA	-82.5	-79.1	-62.5
EBITA margin	-5272.8%	-6266.7%	-4194.5%
Amortization of intangibles	2.1	2.1	2.1
EBIT	-84.6	-81.2	-64.6
EBIT margin	-5404.3%	-6429.8%	-4332.7%
Pre-tax income	-12.0	-26.5	-66.5
Income taxes	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%
Net income	-12.0	-26.5	-66.5
Net margin	-764.5%	-2096.4%	-4460.1%

Diluted EPS	($0.12)	($0.66)	($11.53)
Shares outstanding (diluted)	103.1	40.0	5.8

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.